CenExel Psychiatric Research Expert Presents Data at Schizophrenia International Research Society
- Wall Street ends down as data spooks investors awaiting Fed report
- Roblox (RBLX) Lower as DAUs Fall Sequentially
- DraftKings (DKNG) Plunges as Hindenburg's Report Indicates Betting Company's Links to Black Market Operations
- Oracle (ORCL) Tops Q4 EPS by 23c
- U.S. retail sales take step back as spending pivots to services, trend remains strong
Robert Litman, MD, Discusses Poster on Stress and Coping with COVID-19 in Psychiatric Research
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SALT LAKE CITY, April 19, 2021 /PRNewswire/ -- Robert E. Litman, MD, Founder and Medical Director at CBH Health (Gaithersburg, MD), a CenExel Clinical Research Center of Excellence, will discuss data from a poster presentation entitled, "Stress and Coping with the COVID-19 Pandemic: A Survey of Psychiatric Patients at Clinical Trial Sites" during the 2021 Congress of the Schizophrenia International Research Society (SIRS), to be held April 17- 21, 2021 as a virtual conference.
The poster will be displayed in Session 3 (from 8:00 – 9:00 AM EDT) and in Session 4 (12:15 – 1:15 PM EDT) on Monday, April 19, 2021. These will be interactive sessions where virtual attendees can meet with Dr. Litman to discuss the survey methodology and results.
The presentation will cover disruptive aspects of the pandemic on psychiatric study populations and report on data analyzed from a survey of 94 trial patients diagnosed with either bipolar disorder, major depressive disorder, or schizophrenia. The multi-site survey was conducted between June and September 2020 at three CenExel research facilities: CBH Health, Research Centers of America (Hollywood, FL), and Atlanta Center for Medical Research (Atlanta, GA).
"Despite elevated levels of COVID-19 related stress in patients with serious mental illness, we found that these patients were able to safely and productively participate in clinical trials," said Dr. Litman. "The staff and procedures at the research site can play an instrumental role in helping these study participants cope with their psychological stress."
"Throughout the pandemic, CenExel has continued to enroll thousands of patients and conduct more than 100 clinical trials in nearly two dozen therapeutic areas," said Tom Wardle, CEO of CenExel Clinical Research. "We believe the findings from this psychiatric patient survey will be instructive to other research sites and may benefit pharmaceutical trial sponsors during this very challenging time."
For more information on the 2021 Congress of the Schizophrenia International Research Society, go to https://schizophreniaresearchsociety.org/
Media Contact: media@CenexelResearch.com
About CenExel Clinical ResearchCenExel Clinical Research (www.CenexelResearch.com) provides unparalleled medical and scientific support in the design and execution of clinical trials. The attention to detail assures quality, reliable results and has helped CenExel to consistently achieve and exceed patient recruitment goals. CenExel Centers of Excellence have conducted thousands of studies, the variety and complexity of which have resulted in a vast depth of experience and insight for the principal investigators and research staff in each facility. The CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that their clients achieve their clinical research goals.
View original content to download multimedia:http://www.prnewswire.com/news-releases/cenexel-psychiatric-research-expert-presents-data-at-schizophrenia-international-research-society-301271765.html
SOURCE CenExel Clinical Research
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Azure Power Announces Results for Fiscal Fourth Quarter 2021
- CF Energy Updates Corporate Presentation
- Maple Leaf Foods Inc. Announces Appointment of Tom Hayes to Board of Directors
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!